Second is that trials using fetal infection as an endpoint will be prolonged since vaccine administration must occur preconception. Third, behavioral changes by subjects will affect infection rates, and controls for behavioral changes will have to be in place in any clinical trial. Fourth, not all...
This pessimism ignored the fact that a pioneering clinical trial of the CMV Towne strain live attenuated vaccine had significantly reduced the clinical severity of cases of CMV disease in allograft recipients,2 which we would nowadays interpret as a reduced peak viral load post-transplant.3 The pes...
the National Institutes of Health (NIH) announced. The phase 1 trial, which aims to enroll 95 people without HIV in South Africa and the US, will evaluate the safety of the vaccine as well as its ability to trigger an HIV-specific immune re...
Vaccine-enhanced donor lym- phocyte infusion (veDLI). Hematology 2006: 486–491 73. Sakagawa H, Azuma H, Fujihara M, Ikeda H (2006). Clinical-scale expansion of human cytomegalovi- rus-specific cytotoxic T lymphocytes from periph- eral blood mononuclear cells requiring single-pep- tide ...
ClinicalTrials数据库提供临床试验Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge的登记号NCT00373412,试验分期Phase 1以及申办者University of California, San Francisco的信息,更过关于临床试验的其他信息查询就在戊戌数据美国
We conducted a secondary analysis of data and serum from adults with well-controlled HIV infection from an inactivated polio vaccine trial (224 subjects) and a pneumococcal conjugate vaccine study (128 subjects). We evaluated the association of CMV, HBV, or HCV co-infection with post-vaccination...
Cytomegalovirus vaccine development. Curr Top Microbiol Immunol. 2008;325:361–82. CAS PubMed PubMed Central Google Scholar Rieder F, Steininger C. Cytomegalovirus vaccine: phase II clinical trial results. Clin Microbiol Infect. 2014;20(Suppl 5):S95–102. Google Scholar Fu TM, An Z, Wang...
Cytomegalovirus vaccine development. Curr Top Microbiol Immunol. 2008;325:361–82. CAS PubMed PubMed Central Google Scholar Rieder F, Steininger C. Cytomegalovirus vaccine: phase II clinical trial results. Clin Microbiol Infect. 2014;20(Suppl 5):S95–102. Google Scholar Fu TM, An Z, Wang...
Adenovirus vector-based vaccine is a promising approach to protect HIV infection. However, a recent phase IIb clinical trial using the vector did not show ... M Shoji,S Yoshizaki,H Mizuguchi,... - 《Plos One》 被引量: 17发表: 2012年 A Mortality Analysis of the Cytomegalovirus (CMV) Infe...
[15] Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV. Retrieved September 21, 2023, from https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-announces-first-particip...